Low TCR diversity indicates a severely impaired immune status of patients (Teng et al., 2015; Chen and Mellman, 2017; Snyder et al., 2017), and prospective studies in melanoma patients suggested that peripheral tumor-specific clones are likely to be concentrated in the CD8+PD-1+ subset (Gros et al., 2016). This evidence concerns the gene CD8A and neoplasm.